Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Liminal BioSciences Inc. PFSCF


Primary Symbol: LMNL

Liminal BioSciences is a biopharmaceutical company focused on the discovery and development of novel, small molecule drug candidates for the treatment of patients suffering from fibrotic or inflammatory diseases that have a high unmet medical need. Liminal BioSciences operates on an integrated basis from our talent hubs in Laval, Quebec, Canada, and Cambridge, UK. Our common shares are listed for trading on the Nasdaq Global Market.


NDAQ:LMNL - Post by User

Bullboard Posts
Comment by sah1on May 06, 2017 8:48am
339 Views
Post# 26211993

RE:RE:RE:RE:RE:RE:RE:RE:Diabetic Foot Ulcers - plasminogen

RE:RE:RE:RE:RE:RE:RE:RE:Diabetic Foot Ulcers - plasminogenIt would make sense that all IV related apps of Pg would be phase 4 studies, such as acute Pg deficiency and severe burns. But in the case of wound healing, where the formulation is different as well as the method of application, I wonder what will be the clinical trial process. Hopefully, Phase 1 safety studies can be avoided since we are dealing with micro grams in wound healing applications BUT I think placebo controlled Phase 2/3 studies may be required in these apps. I look forward to next week's AGM to see what clarity can be brought to this issue and the many others facing the company.
Bullboard Posts